Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : RedHill Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.
Brand Name : RHB-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2021
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : RedHill Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?